home / stock / gild / gild articles

GILD Articles, Gilead Sciences Inc. - From 04/24/24

Stock Information
Company Name: Gilead Sciences Inc.
Stock Symbol: GILD
Market: NASDAQ
Website: gilead.com
Menu
GILD GILD Quote GILD Short GILD News GILD Articles GILD Message Board
Get GILD Alerts

News, Short Squeeze, Breakout and More Instantly...
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? | Benzinga

Wednesday, HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its Investigational New Drug (IND) application for H...
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week | Benzinga

As the market runs into rough weather, the importance of the upcoming week’s earnings cannot be emphasized enough. A lot is riding on the ear...

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies | Benzinga

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings??...

If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today | Benzinga

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.77% on an annualized basis producing an average annual return...
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter | Benzinga

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...

Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst | Benzinga

Bank of America Securities downgrades European drugmaker Galapagos NV (NASDAQ:GLPG) to underperform, citing few catalysts in the near term. Gal...

Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why | Benzinga

Xilio Therapeutics Inc (NASDAQ:XLO) shares are surging as the company announced an exclusive license agreement with Gilead Sciences Inc&n...
Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production | Benzinga

Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treat...

If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,100 Today | Benzinga

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 4.71% on an annualized basis producing an average annual return...

Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley | Benzinga

Morgan Stanley initiates Arcellx Inc (NASDAQ:ACLX), noting a differentiated CAR-T platform for blood cancer backed by an established...
Previous 10 Next 10